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The pros of plurality for tuberculosis burden estimates 
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Tuberculosis (TB) is now reckoned to be the leading infectious cause of death.1 That multiple people 
die every minute from a cheaply curable disease, which has been reduced to incidence rates of below 
0.01% per year in many rich countries, is plainly unacceptable. The evidence to support statements on 
the extent of the TB pandemic most often comes from the burden estimates released annually by the 
Global TB Programme at the World Health Organization (WHO).1 The other set of global TB disease 
burden estimates are those of the Global Burden of Disease studies from the Institute of Health 
Metrics and Evaluation (IHME), which include TB as part of a large range of causes of deaths and 
disability.2 Both sets of estimates for mortality rely on high quality vital registration systems in 
countries where they exist; unfortunately, in many high TB burden countries such systems are 
lacking, and differences in the modelling approaches used to leverage other data sources (and to some 
extent, the inclusion of additional mortality data such as verbal autopsy by IHME) lead to differences 
between the WHO and IHME estimates, particularly at the country level.  
 
In this issue of International Journal of Epidemiology, García-Basteiro and colleagues systematically 
compare the two sets of TB mortality estimates, finding a 29% difference globally relative to their 
average.3 While there is 92% correlation between this set of WHO and IHME country-level estimates, 
the global difference is larger than it has been in previous estimation rounds and is clearly worthy of 
scrutiny. García-Basteiro and colleagues find that the difference is largest in countries with a low case 
detection rate (which is likely to correlate negatively with availability or quality of vital registration 
data) and countries with recent prevalence surveys (suggesting the importance of methodological 
differences in utilizing such data in indirect estimates of mortality). It is striking that of the 12 
countries with the largest absolute difference in estimated TB deaths in this analysis, none was based 
straightforwardly on vital registration data in the 2016 WHO round considered here. As authors from 
both WHO4 and IHME 2 have noted: the differences are greatest where the data are weakest; where 
good quality vital registration data exist, as one would hope, the estimates closely align. The obvious 
implication of this is that the best way to improve TB mortality estimates is to promote the wider 
development of high quality vital registration systems (which WHO is supporting), and to undertake 
mortality surveys in the interim. 
 
Estimates of disease burden are undeniably important. They are used in advocacy, planning and 
prioritization, development assistance funding applications, and in allocating resources. They are also 
used to monitor progress at the global level, for example towards the targets of the End TB strategy. 
This implies that there is power associated with generating estimates,5 whether sought for or not, and 
its legitimacy rests partially on the reproducibility and transparency to scientific criticism of the 
results. Initiatives such as the GATHER (Guidelines for Accurate and Transparent Health Estimates 
Reporting) statement and checklist6 should help spur improvements in this regard, although 
challenges are likely to remain around ownership and public availability of certain data, and around 
the sheer complexity of some of the methods and their communication.  
 
Communication is key, however. While it can create recognized challenges for advocacy when burden 
estimates change in light of new evidence, and subsequent revisions have been misinterpreted as 
trends, it is crucial for the legitimacy and utility of such estimates that they are based on the best 
possible current science and data. Creating a wider understanding of the processes of estimation, and 
the limitations and uncertainties inherent in their outputs would help avoid detracting from valid 
messages when revisions occur, and also reduce the chance of estimates being misused. 
 
Ultimately, the fact that this paper exists should be a cause for celebration. That more than one body 
undertakes independent estimates of the global toll from one of mDQNLQG¶VPRVWLPSRUWDQWSDWKRJHQV
should be applauded. That the results have been available in a form that enabled this comparative 
analysis is also positive. Competition is likely to be healthy, and collaboration and cross-fertilization 
do occur (e.g. the use of IHME mortality data for 18 countries by WHO in 2017, where IHME had 
access to additional data or used  improved approaches to TB/HIV miscoding). Far from a duplication 
of effort, without this plurality of approach, comparative analyses such as this one by García-Basteiro 
and colleagues would not be possible. Here, country estimates that differ most and are likely less 
reliable have been flagged for additional attention. It is these countries where methodological 
refinements and/or additional data would be most useful in improving estimates. The analysis itself 
helps communicate that neither source of estimates should be considered completely authoritative, 
and that our understanding is incomplete. However, valid areas of uncertainty must not be used as a 
pretext to undermine the global importance of improving TB control. 
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